Immunotherapy of brain tumors.
The fight against neoplasia still represents a formidable challenge. At the present time the mechanism of cell-mediated immunity seems to offer the most promise. At the same time, one is cautioned by the implication that minimal cell-mediated responses threaten acceleration of tumor growth. Therefore, one is impressed with the need for investigation of these approaches in a model system prior to their application to humans. The data currently available suggest that when active tumor growth is present within the host, a state of immune deficiency exists: cell-mediated immune responses may be quantitatively deficient or this response may be negated by the presence of blocking factor in the serum. Efficient and effective immune responses imply adequate cell-mediated immunity and the absence of blocking factor activity within the serum.
D000917:Antibody Formation; D000936:Antigen-Antibody Complex; D000951:Antigens, Neoplasm; D001500:BCG Vaccine / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007109:Immunity; D007111:Immunity, Cellular; D007167:Immunotherapy
D000936:Antigen-Antibody Complex; D000951:Antigens, Neoplasm; D001500:BCG Vaccine